Related Experiment Video
Updated: Oct 31, 2025

10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.5K
Molecular Profile of Advanced Cutaneous Squamous Cell Carcinoma
Jordan Jones1,2,3, Megan Wetzel1,2,3, Timothy Brown1,2,3
1Drs. Jones and Brown are with the Division of Dermatology of the Department of Medicine at the University of Louisville in Louisville, Kentucky.
The Journal of Clinical and Aesthetic Dermatology
|June 30, 2021
Summary
Advanced cutaneous squamous cell carcinoma (cSCC) patients may benefit from targeted therapy. Identifying unique genetic mutations, like ERBB3, can guide treatment and improve outcomes in difficult-to-treat cases.
Area of Science:
- Oncology
- Genomics
- Dermatology
Background:
- Advanced cutaneous squamous cell carcinoma (cSCC) often presents with high tumor mutation burdens (TMBs).
- Many patients with advanced cSCC cannot tolerate immunotherapy due to comorbidities or immunosuppression.
- Targeted therapy presents a potential treatment avenue if specific genetic mutations are identified.

